Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma - Related Studies

Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

This study is ongoing, but not recruiting participants.

Study NCT00004066. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Ovarian Cancer
		Sarcoma
		Small Intestine Cancer

2	Additional conditions recognized in this trial
		Duodenal Neoplasms
		Ileal Neoplasms
		Intestinal Neoplasms
		Jejunal Neoplasms
		Leiomyosarcoma
		Ovarian Neoplasms

3	More general conditions related to this trial
		Adnexal Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Duodenal Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Ileal Diseases
		Intestinal Diseases
		Jejunal Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Connective and Soft Tissue
		Neoplasms, Muscle Tissue
		Ovarian Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		docetaxel
		filgrastim
		gemcitabine hydrochloride

5	Additional drug interventions recognized in this trial
		Gemcitabine

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Memorial Sloan-Kettering Cancer Center
		National Cancer Institute (NCI)